Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159426" target="_blank" >RIV/00098892:_____/25:10159426 - isvavai.cz</a>
Result on the web
<a href="https://academic.oup.com/ehjqcco/article/11/6/816/8096634?login=true" target="_blank" >https://academic.oup.com/ehjqcco/article/11/6/816/8096634?login=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1093/ehjqcco/qcaf018" target="_blank" >10.1093/ehjqcco/qcaf018</a>
Alternative languages
Result language
angličtina
Original language name
Implantable cardioverter defibrillators in heart failure with reduced ejection fraction after myocardial infarction: the need for contemporary evidence
Original language description
Sudden cardiac death is an important cause of death after myocardial infarction. Most of these episodes are considered the result of ventricular arrhythmia, with occurrence higher where myocardial infarction has been complicated by left ventricular systolic dysfunction. The landmark Multicenter Automatic Defibrillator Implantation Trial II (MADIT II) and sudden cardiac death in heart failure (SCD-HeF T) trials, conducted around the turn of the millennium, established that treatment with implantable cardioverter defibrillators was superior to medical therapy for prevention of mortality in this context. Successive European Society of Cardiology guidelines provide a class I recommendation for the use of implantable cardioverter defibrillators for patients with persistent severe left ventricular systolic dysfunction after myocardial infarction and medicine optimization. This narrative review considers the historical randomized clinical trial evidence, the temporal trends in rate and cause of death in this patient population, as well as improvements in medical therapy, and why this necessitates a reappraisal of the benefit of implantable cardioverter defibrillators in the post-myocardial infarction population in contemporary clinical practice. Finally, details of the PROFID-EHRA trial are reported, which seeks to address this critical evidence gap.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
R - Projekt Ramcoveho programu EK
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Heart Journal
ISSN
0195-668X
e-ISSN
1522-9645
Volume of the periodical
11
Issue of the periodical within the volume
6
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
816-824
UT code for WoS article
001472660400001
EID of the result in the Scopus database
2-s2.0-105016585446